Nanoparticle-Mediated Targeting of Cancer Stem Cells

Cancer stem cells (CSCs) represent a subpopulation within tumours endowed with self-renewal capability, differentiation potential and heightened resistance to conventional therapies. Their persistence underlies relapse, metastasis and poor patient prognosis. Nanoparticle-based systems have emerged as versatile platforms to surmount these challenges by enabling controlled delivery, selective recognition and on-demand release of therapeutics directly at CSC niches. Surface functionalisation with antibodies, aptamers or peptides targeting markers such as CD44 and CD133 imparts active homing, while stimuli-responsive materials exploit tumour acidity, enzyme overexpression or hypoxia to trigger payload liberation. Multifunctional constructs co-deliver chemotherapeutics with CSC-specific inhibitors or gene silencers to effect synergistic eradication. Integrating photosensitisers for photodynamic therapy or immune checkpoint inhibitors within nanocarriers further counters hypoxia-driven immune evasion and enhances phagocytic clearance of CSCs. Innovations in deep-penetrating architectures improve access to sanctuary sites, minimise off-target toxicity and permit real-time imaging guidance. Despite promising preclinical outcomes, translation into clinical practice demands rigorous validation of large-scale manufacture, pharmacokinetics, biodistribution and long-term safety. Refinement of targeting ligands, biodegradability profiles and regulatory pathways will be pivotal in realising the full potential of nanoparticle-mediated CSC therapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Nanoparticle-Mediated Targeting of Cancer Stem Cells publication trend

The graph below shows the total number of articles in nanoparticle-mediated targeting of cancer stem cells across all publications each year (not limited to Nature Index journals).

Technical terms

Cancer stem cells (CSCs): A subpopulation of tumour cells with self-renewal and differentiation capacity responsible for metastasis, recurrence and therapy resistance.

Nanoparticle: A nanoscale carrier—often composed of lipids, polymers or inorganic materials—engineered to transport therapeutic agents to specific cells or tissues.

Checkpoint blockade: An immunotherapy approach that inhibits regulatory pathways (e.g. CD47–SIRPα) used by tumour cells to avoid immune clearance.

Hypoxia: Low-oxygen conditions in the tumour microenvironment that promote resistance to therapies and suppress antitumour immunity.

Photodynamic therapy (PDT): A treatment modality wherein a light-activated photosensitiser generates cytotoxic reactive oxygen species to kill targeted cells.

References

1. Genetically engineered nanomodulators elicit potent immunity against cancer stem cells by checkpoint blockade and hypoxia relief. Bioactive Materials (2024).
2. Carrier‐free nanodrugs for stemness inhibition‐enhanced photodynamic therapy. Aggregate (2022).
3. Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. Pharmaceutics (2022).